Aptorum Group
About: Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Employees: 3
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1.08% less ownership
Funds ownership: 2.97% [Q2] → 1.89% (-1.08%) [Q3]
50% less funds holding
Funds holding: 4 [Q2] → 2 (-2) [Q3]
74% less capital invested
Capital invested by funds: $384K [Q2] → $99.7K (-$284K) [Q3]
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Research analyst outlook
We haven’t received any recent analyst ratings for APM.
Financial journalist opinion
Neutral
Business Wire
1 day ago
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2024
NEW YORK--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2024. “Our team and Yoov have spent considerable time and effort on the due diligence process, the negotiation of definitive terms, and the preparation of necessary tra.
Neutral
Business Wire
7 months ago
Aptorum Group Limited Reports 2023 Fiscal Year End Financial Results and Provides Business Update
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2023, and provided an update on corporate developments. Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented, “Throughout 2023, we have maintained a.
Positive
InvestorPlace
9 months ago
5 Investors Betting Big on Aptorum (APM) Group
Clinical-stage biopharmaceutical firm Aptorum (NASDAQ: APM ) is seeing its market value rise dramatically today on a merger between its wholly owned subsidiary and an artificial intelligence (AI) and automation platform. A combination of AI enthusiasm and some support from institutional investors is likely what's helping APM stock rocket higher.
Positive
InvestorPlace
9 months ago
Why Is Aptorum (APM) Stock Up 346% Today?
Aptorum (NASDAQ: APM ) stock is rocketing higher on Wednesday after the biopharmaceutical company announced a merger agreement with YOOV Group. This will be a reverse merger that will see YOOV shareholders hold 90% of the combined company after the deal is complete.
Neutral
Business Wire
9 months ago
Aptorum Group Ltd Announces Entering into an Agreement and Plan of Merger with YOOV Group Holding Ltd and a Split-off Agreement to Separate its Legacy Business
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM), a clinical stage biopharmaceutical company (“Aptorum”), and privately-held YOOV Group Holding Ltd. (“YOOV”) jointly announced today that they entered into an Agreement and Plan of Merger (as it may be amended from time to time, the “Merger Agreement”). The Merger Agreement was approved by Aptorum's and YOOV's boards of directors (each board of directors, the “Board”), respectively. If the Merger Agreement is approved by Ap.
Neutral
Business Wire
1 year ago
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (NASDAQ: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune and infectious diseases, today provided a business update and announced financial results for the six months ended June 30, 2023. “During the first half of 2023, we remained focused on advancing the development of our therapeutic programs. We continue to work towards advancing our A.
Neutral
Business Wire
1 year ago
Aptorum Group Limited Announces Results of 2023 Annual General Meeting of Shareholders
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, announced the results of its 2023 annual general meeting of shareholders, which was held on December 20, 2023, in London. At the annual general meeting, the required number of shareholders of the Company: Re-elected all Class I directors to hold office.
Neutral
Business Wire
1 year ago
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 20, 2023
NEW YORK & LONDON--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced that it will hold its 2023 annual general meeting of shareholders at its London office located at 17 Hanover Square, Mayfair London, England W1S 1BN at 1:00 p.m. London Time on December 20, 2023 (8:00 a.m. Eastern Standard Time on Decemb.
Charts implemented using Lightweight Charts™